Clinical Trial Results:
Effects of single doses of Stalevo 200 and levodopa/carbidopa 200/50 mg on striatal 11C-raclopride binding potential in Parkinson’s disease patients with wearing-off symptoms. An open, randomised, active-controlled, two-period crossover study.
Summary
|
|
EudraCT number |
2007-002496-14 |
Trial protocol |
FI |
Global completion date |
27 Mar 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Sep 2016
|
First version publication date |
02 Sep 2016
|
Other versions |
|
Summary report(s) |
EFFECTS OF SINGLE DOSES OF STALEVO 200 AND LEVODOPA/CARBIDOPA |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.